Randomized controlled trials assessing the benefits of NAT2 pharmacogenomic guided LFT monitoring and isoniazid dosing regimen are imperative for deriving conclusive evidence on the benefits of incorporating NAT2 genotyping in the clinical management of TB patients. Here, NAT2 is linked to tuberculosis.